NSE: IPCALAB | BSE: 524494

Mid-range Performer

Download real time

1350.50 2.10 (0.16%)

110.9K NSE+BSE Volume

NSE 25 Sep, 2025 3:31 PM (IST)

34,262.8

Market Cap

High in industry

0.8

Beta 1Year

Very Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Ipca Laboratories Ltd.

17 Nov 2021

1350.50

0.16%

Q2FY22 Result Update - Weak quarter; outlook remains positive - BUY

Buy: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Q4FY22/Q1FY23. Domestic business (45% of total sales) continues to remain on strong footing and should continue to outperform IPM. Strong API capabilities and diversified model benefit IPCA in the current environment. We recommend Buy' rating on the stock with target price of Rs 2,450 based...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

17 Nov 2021

1350.50

0.16%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Maintain BUY due to good traction in domestic formulations and sustainable growth amid some margin pressure in medium term Target Price and Valuation: We value Ipca at | 2490 i.e. 26x P/E on FY23E EPS...

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

07 Aug 2021

1350.50

0.16%

Q1FY22 Result Update - High base plays spoilsport for earnings growth - ACCUMULATE

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We increase our earnings estimates by 6% for FY23E as we upgrade our growth assumptions on India formulations and UK generics. With tailwind in acute therapy products (mainly Anti-infective medicines), we increase our...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

01 Jun 2021

1350.50

0.16%

Q4FY21 Result Update - Swapping lower sales growth with better core margin - Accumulate

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

One-off sales of CQ and HCQS to impact growth and margin in FY22E We increase our earnings estimates by 9.7%/7.7% for FY22E/23E while revenue cut by 3.3%/3.1% in FY22E/FY23E. Expansion in EBITDA margins by 170bps to 25.2% (management guidance of 25.0-25.5%) due to reduction in...

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

31 May 2021

1350.50

0.16%

4Q - an aberration; outlook remains intact

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA)'s 4QFY21 performance was below expectations, weighed by moderation in the Domestic Formulation (DF) segment and API sales. However, IPCA remains on track to deliver healthy mid-teen YoY growth in the Branded Generics segment. Increased business share from the integrated manufacturing value chain and better operating leverage in DF would drive improvement in profitability going forward adjusted for onetime business from Hydroxychloroquine Sulfate (HCQS) in FY21. We lower our EPS estimate by 5%/2% for FY22/FY23E, reflecting a) sales growth constraints in the API/Generics segment and b) an increase in...

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

31 May 2021

1350.50

0.16%

IPCA Laboratories

Hold: Ipca Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

Domestic formulations comprise 37% of FY21 revenues. The domestic performance has been volatile at times due to presence of anti-malarials in the portfolio. However, with incremental growth in other therapies, especially non-communicable diseases like pain management, cardiodiabetology, etc, the overall portfolio is poised for steady growth. We expect...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

11 Apr 2021

1350.50

0.16%

On a steady footing

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

IPCA has reported sales of ~INR3.8b (7% of sales) in the Branded export segment over the past 12M (down 5% YoY), largely due to the COVID-led disruption. However, with a reduction in daily new cases in the Middle East / West Africa, the segment is expected to see growth recovery....

Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr

Ipca Laboratories Ltd.

11 Mar 2021

1350.50

0.16%

According to total sales audit data from IMS, Indian Pharma Market (IPM) grew 2.6% YoY in...

Hold: Ipca Laboratories Ltd.

Target

Emkay

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

16 Feb 2021

1350.50

0.16%

Monthly Update - IPM grapple for normalized growth after COVID

Accumulate: Ipca Laboratories Ltd.

Prabhudas Lilladhar

IPM is struggling for growth above 10% even after MoM abating COVID concerns and with MRs, physician activities almost reaching pre-COVID level. We believe key reasons for growth below par are (i) subdued new prescription (Rx) leading to volume de-growth (ii) digital marketing yield going south and (iii) sustained lower demand of acute products. Cardiac and anti-diabetic growth takes a breather in Jan-21 at 8.8% and 5.3% after reporting double digit growth in most months during lockdown. While amongst top therapies Gastro and VMN reported double digit growth of 14%...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

06 Feb 2021

1350.50

0.16%

Q3FY21 Result Update - Growth momentum continues across segments - Accumulate

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We reduce our earnings estimate by 3%/6% for FY22/23E, as we trim our growth projection for selective countries in branded and generic export formulation segment. 3QFY21 revenue was in-line with our estimate, however there was an EBITDAM beat of 250bps due to continued lower marketing expense. IPCA reaffirmed its growth guidance for FY22-23E with 1) India...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Is Ipca Laboratories Ltd. worth buying?

367 Votes:

Buy 80.38%

Sell 9.81%

Hold 9.81%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf